Quarter ended on March 31, 2025Data in Crores of INR
Revenue₹ 429.88+34.77% from last year
Operating profits₹ 199.81+37.7% from last year
Net income₹ 141.94+46% from last year
Data is unavailable
Data is unavailable
View detailed balance sheet
Profitability ratios
ROA19.17%
ROE21.88%
ROCE29.13%
EPS29.45%
Net profit margin30.3%
Operating profit margin45.82%
Dividend per share8.75%
Operational ratios Quick ratio4.84%
Current ratio6.3%
Interest coverage130.57%
Assets turnover0.63%
Debt to equity
Valuation ratios P/E ratio46.12%
P/B ratio9.46%
Dividend yield0.65%
EV/EBITDA
Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology, supplying too many countries including regulated markets, such as the United States, Europe and Japan and India. It commanded a market share of over 20% by volume in 2022 across identified fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine. In 2016, it launched its formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States.
Show figures in :
